Vir Biotechnology (VIR) Cash from Financing Activities (2018 - 2026)

Vir Biotechnology has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $162.5 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $162.5 million, up 27077.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $165.7 million (up 3328.01% YoY), and the FY2025 annual result was $3.8 million, down 13.74% from the prior year.
• Cash from Financing Activities came in at $162.5 million for Q1 2026 at Vir Biotechnology, up from $1.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $162.5 million in Q1 2026 to a low of $31000.0 in Q3 2024.
• The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $12.5 million.
• Across the five-year window, Cash from Financing Activities sank 93.52% in 2024 and soared 27077.76% in 2026, its largest moves.
• Vir Biotechnology's Cash from Financing Activities stood at $2.0 million in 2022, then slipped by 16.46% to $1.7 million in 2023, then dropped by 24.82% to $1.3 million in 2024, then decreased by 17.74% to $1.0 million in 2025, then soared by 15542.25% to $162.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $162.5 million (Q1 2026), $1.0 million (Q4 2025), and $102000.0 (Q3 2025), per Business Quant data.